Discounted Cash Flow
Twist Bioscience Corp.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | — | — | — | — |
| 2017 | $10.8m | $-59.3m | $-57.9m | -550.8% | — |
| 2018 | $25.4m (136.2%) | $-71.2m (-20.1%) | $-69.9m (-20.7%) | -280.2% (49.1%) | — |
| 2019 | $54.4m (113.9%) | $-107.7m (-51.1%) | $-102.7m (-47.0%) | -198.0% (29.3%) | — |
| 2020 | $90.1m (65.7%) | $-139.9m (-30.0%) | $-152.1m (-48.1%) | -155.3% (21.6%) | — |
| 2021 | $132.3m (46.9%) | $-152.1m (-8.7%) | $-139.3m (8.4%) | -114.9% (26.0%) | $-3.15 |
| 2022 | $203.6m (53.8%) | $-217.9m (-43.2%) | $-226.2m (-62.4%) | -107.0% (6.9%) | $-4.04 (-28.3%) |
| 2023 | $245.1m (20.4%) | $-204.6m (6.1%) | $-170.3m (24.7%) | -83.5% (22.0%) | $-3.60 (10.9%) |
| 2024 | $313.0m (27.7%) | $-208.7m (-2.0%) | $-69.2m (59.4%) | -66.7% (20.1%) | $-3.60 (0.0%) |
| 2025 | $376.6m (20.3%) | $-77.7m (62.8%) | $-75.6m (-9.3%) | -20.6% (69.1%) | $-1.30 (63.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.